# Timing of Immunotherapy in Melanoma

> **NCT07696715** · NA · RECRUITING · sponsor: **Radboud University Medical Center** · enrollment: 170 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Timing of first administration (early morning)
- **OTHER:** Timing of immunotherapy (afternoon)

## Key facts

- **NCT ID:** NCT07696715
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2029-09-30
- **Final completion:** 2033-09-30
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2026-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07696715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07696715, "Timing of Immunotherapy in Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07696715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*